Abstract
Influenza remains a significant threat to human and animal health. Assessing serological protection against influenza has relied upon haemagglutinin inhibition assays, which are used to gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology studies. Here, we adapt our high-throughput live virus microneutralisation assay for SARS-CoV-2, benchmark against haemagglutinin inhibition assays, and report serological vaccine responsiveness in a cohort of older (>65yo) community dwelling adults (n=73), after the adjuvanted 2021-22 Northern Hemisphere quadrivalent vaccine. We performed both assays against all four viruses represented in the vaccine (A/Cambodia/H3N2/2020, A/H1pdm/Victoria/2570/2019, B/Yamagata/Phuket/2013, BVIC/Washington/02/201), using sera drawn on days 0 [range: d-28 to d0], 7 [d6-10] and 182 [d161-196] with respect to vaccination. We found population-level concordance between the two assays (Spearman’s correlation coefficient range 0.48-0.88; all P≤1.4 × 10−5). The improved granularity of microneutralisation was better able to estimate fold-changes of responses, and quantify the inhibitory effect of pre-existing antibody. Our high-throughput method offers an alternative approach to assess influenza-specific serological responses with improved resolution.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MAL is a Lister Institute Prize Fellow. EJC is supported by a Medical Research Council Clinician Scientist Fellowship (MR/X006751/1). This work was supported by the NIHR Cambridge BRC, the Dunhill Medical Trust (RPGF1910/223 to MAL), the Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428, and the Campus Capability Core Grant to the Babraham Institute), the Medical Research Council (MR/X006751/1 to EJC), a UKRI Frontier award (EP/X022382/1 to MAL), in part funded by the NIH Centres of Excellence in Influenza Research and Response program Penn-CEIRR contract (75N93021C00015), and by the Francis Crick Institute which receives its core funding from Cancer Research UK (CC1114, CC2230, CC0102), the UK Medical Research Council (CC1114, CC2230, CC0102), and the Wellcome Trust (CC1114, CC2230, CC0102).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
AgeVax was approved by the Yorkshire & The Humber South Yorkshire Research Ethics Committee (IRAS 277259, REC 20/YH/0101).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymised data and R code are freely available via github.
